Everest Medicines grants options, awards to employees and directors

Everest Medicines (HKEX:1952) has announced the grant of 4,451,533 share options under its Post-IPO Share Option Scheme to 185 employees, including two directors, on April 1, 2025, with an exercise price of HKD 55.61 each. Additionally, the company granted 1,145,897 awards and a maximum of 253,159 performance target awards under the Pre-IPO ESOP to 193 and 5 non-connected award grantees respectively. The company also resolved to grant 205,911 Performance Target Awards to Mr. Yongqing Luo, 92,660 Performance Target Awards to Mr. Ian Ying Woo, and 4,500 awards to another Connected Award Grantee subject to acceptance and approval at the AGM. The vesting period is generally four years, with varying commencement dates. The grants aim to attract, retain, and incentivize employees and align their interests with the company's long-term growth.